Atrial Fibrillation Clinical Trials in Detroit, Michigan

4 studies are recruiting for atrial fibrillation in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Fourth Left Atrial Appendage Occlusion Study

   LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Locations

   150 in total

   Run by

   Hamilton Health Sciences Corporation

   See if you can join NCT05963698 on ClinicalTrials.gov

2. A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation

   The main goal of this study is to find out how well BAY 3670549 works, how safe it is, how well people can tolerate it, and how the body handles the medicine. The study will compare BAY 3670549 to a placebo (a dummy treatment with no active medicine) in people with AF who need a treatment called el…

   Stage

   Phase 2

   Ages

   18 to 85

   Site

   Henry Ford Hospital - Cardiology, Detroit, Michigan

   Locations

   29 in total

   Run by

   Bayer

   See if you can join NCT07625215 on ClinicalTrials.gov

3. The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

   REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in parti…

   Stage

   Phase 3

   Ages

   22 to 85

   Site

   Henry Ford Health, Detroit, Michigan

   Locations

   93 in total

   Run by

   Johns Hopkins University

   See if you can join NCT05836987 on ClinicalTrials.gov

4. Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

   Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in b…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford Hospital, Detroit, Michigan

   Locations

   187 in total

   Run by

   Yale University

   See if you can join NCT03907046 on ClinicalTrials.gov